Mitigating ipatasertib‐induced glucose increase through dose and meal timing modifications-Reference-Cited by-同舟云学术

Mitigating ipatasertib‐induced glucose increase through dose and meal timing modifications

Published:2022-11-16 Issue:12 Volume:15 Page:2989-2999
ISSN:1752-8054
Container-title:Clinical and Translational Science
language:en
Short-container-title:Clinical Translational Sci

Author:

Sutaria Dhruvitkumar S.¹,Agarwal Priya¹,Huang Kuan‐Chieh¹,Miles Dale R.¹,Rotmensch Jacob¹,Hinton Heather²,Gallo Jorge Daniel²,Rasuo Grozdana²,Sane Rucha S.¹

Affiliation:

1. Genentech, Inc. South San Francisco California USA

2. F. Hoffmann‐La Roche AG Basel Switzerland

Publisher

Wiley

Subject

General Pharmacology, Toxicology and Pharmaceutics,General Biochemistry, Genetics and Molecular Biology,General Medicine,General Neuroscience

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cts.13420

Reference17 articles.

1. Integrative Clinical Genomics of Advanced Prostate Cancer

2. A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors

3. Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer

4. Cell Autonomous Role of PTEN in Regulating Castration-Resistant Prostate Cancer Growth

5. Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Phase Ib, Open-label Study Evaluating the Safety and Efficacy of Ipatasertib plus Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer;Clinical Cancer Research;2023-06-20

2. Risk Factors of Hyperglycemia After Treatment With the AKT Inhibitor Ipatasertib in the Prostate Cancer Setting: A Machine Learning–Based Investigation;JCO Clinical Cancer Informatics;2023-04

3. Drug–Drug Interaction Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Ipatasertib in Combination with Darolutamide in Patients with Advanced Prostate Cancer;Pharmaceutics;2022-10-01